Trade BioNTech BNTX

Magbenta
 Bumili

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

BioNTech news

number1 2025 Sep 22, 22:50

BioNTech Stock Surges on Regulatory Nod and Analyst Upgrade

number1 2025 Jul 11, 03:38

AI Podcast: Dollar Weakness and Investment Implications

number1 2025 Jul 11, 03:38

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Mga pinakabagong balita

Ipakita nang marami
number1 2025 Oct 21, 00:00

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

number1 2025 Oct 21, 00:00

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

number1 2025 Oct 21, 00:00

US Government Shutdown: Economic Fallout and Political Impasse

number1 2025 Oct 21, 00:00

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

number1 2025 Oct 19, 00:00

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

number1 2025 Oct 18, 00:00

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

number1 2025 Oct 18, 00:00

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

number1 2025 Oct 18, 00:00

Fed's Rate Cut Conundrum: An Outlook to 2026

Info

Spread

0.9666

Spread (%)

1.0109 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Biyernes

14:31 - 20:59

Lunes

14:31-20:59

Martes

14:31-20:59

Miyerkules

14:31-20:59

Huwebes

14:31-20:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

23083724800

Natitirang Pagbabahagi

240455450

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

2022-06-17

Araw ng Pag-alis ng Karapatan sa Dividend

2022-06-02

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-2.78

Alamin ang Higit Pa Tungkol sa Instrumentong ito

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Mga kaugnay na instrumento

Asset
Magbenta
Bumili
Change (%)

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon
view_all_instruments

latest_education_articles

Ipakita nang marami
Frances Wang 2025 Feb 17, 16:00

Pi network price prediction 2025: Will Pi Network price go up or down?

Stocks
Frances Wang 2025 Jan 21, 16:00

What is the XRP price prediction for 2025: Will XRP reach $1000?

Crypto
Frances Wang 2024 Dec 29, 16:00

What is the USD DXY index and how does the DXY reflect the dollar's value?

Indices
Trustpilot